This Medudy Master Class Series is a video tutorial for physicians on prostate cancer.
This four-part module focuses on metastatic castration-resistant prostate cancer (mCRPC) and is presented by Prof. Dr. Martin Bögemann, senior physician in urology and pediatric urology at the University Hospital in Münster.
The first section addresses first-line therapy for mCRPC, taking into account prior treatment for mHSPC. The second section then focuses on the approach to sequential therapy. The third part reviews current studies on PARP inhibitors and ARPI/PARPI combination therapy, as well as the relevance of BRCA1/2 mutations in this context. Finally, the fourth part offers an outlook on the future of treatment for mCRPC and presents therapeutic approaches currently undergoing clinical trials.
Note: All "speakers" appearing in the Medudy videos are AI-based avatars used to improve the didactics of the videos. The people on whom the avatars are based have explicitly consented to their use. All content is based on high-quality scientific sources and is created and reviewed by the Medudy medical team.
The course was created with the kind support of Johnson & Johnson, Astra Zeneca, Bayer, Astellas and AMGEN.
By the end of this course, you will know:
- The Importance of First-Line Therapy in mCRPC and Criteria for Treatment Selection.
- The approach to sequential therapy, taking current studies into account.
- Recent studies on PARP inhibitors and ARPI/PARPI combination therapy, as well as the significance of BRCA1/2 mutations in this context.
- New therapeutic approaches that are currently undergoing clinical trials and could expand the therapeutic landscape in the future.
